Decision Resources projects same U.S., Europe patient share of ulcerative colitis biologic
WALTHAM, Mass. A new report by Decision Resources revealed that a biological therapy with a mechanism of action other than tumor necrosis factor-alpha inhibitors, used for the treatment of moderate to severe ulcerative colitis, would earn a 25% patient share in both the United States and Europe.
The report, “Ulcerative Colitis: Gastroenterologists Identify Emerging Drugs That Will Challenge the Benchmark Therapy Infliximab for Moderate to Severe UC,” finds that two emerging TNF-alpha inhibitors — Abbott/Eisai’s Humira and Centocor Ortho Biotech/Merck/Mitsubishi Tanabe Pharma/Janssen’s Simponi — will earn Decision Resources’ proprietary clinical gold standard status for ulcerative colitis in 2013 following their approval for the indication. Both Humira and Simponi have competitive advantages over sales-leader Remicade in efficacy, delivery, and safety and tolerability.
“Although clinical trial data are limited, interviewed experts believe that both Humira and Simponi’s fully human composition will translate into incremental advantages in efficacy for maintenance of remission and maintenance of response compared to Remicade, which is a chimeric monoclonal antibody,” said Decision Resources analyst Kathryn Benton.
Tylenol Arthritis caplet recall becomes a bigger headache
NEW YORK Johnson & Johnson has expanded its voluntary recall of Tylenol Arthritis caplets in the wake of consumer reports of a moldy smell that can cause nausea and sickness. The recall now includes all product lots of the Arthritis Pain caplet 100-count bottles with the red EZ-Open cap.
Prior to this, the company had recalled five lots of the product in November, citing similar reasons, with user complaints of nausea, stomach pain, vomiting and diarrhea.
According to J&J, the odor is coming from trace amounts of 2,4,6-tribromoanisole — a chemical used to treat wooden pallets that transport and store packaging materials — which is believed to be the result from the breakdown of another chemical used in the manufacture of the drug.
To date, the side effects have been “temporary and non-serious,” although the health effects of the compound have not been studied.
The recall only affects the specific lots reported, and does not extend to any other Tylenol pain products.
J&J is moving its production of Tylenol Arthritis Pain caplets 100-count to another plant, and plans to reintroduce the product in January.
J&J is advising consumers seeking a refund or replacement to call (888) 222-6036.
P&G adds new products to Vicks DayQuil line
CINCINNATI Procter & Gamble on Wedneday introduced Vicks DayQuil Mucus Control and DayQuil Mucus Control DM. These products, which work for four hours, help loosen and thin mucus.
Vicks DayQuil Mucus Control provides mucus relief, making coughs more productive. In addition, DayQuil Mucus Control DM contains a cough suppressant for combined comfort of thinning mucus and controlling cough.
“When you are sick, your body produces excess mucus, which also becomes thicker and more difficult to clear,” stated Matt Kemme, brand manager, Vicks. “We’ve uncovered an insight that some consumers are restricting their mucus treatment to avoid coughing up phlegm in public,” he said. “The expectorant agent in Vicks DayQuil Mucus Control acts for four hours, helping people control over when and where they expel their mucus out.”
Average retail price ranges between $6.49 and $7.29.